SCHEMBL2064602

SCHEMBL2064602

N=C(NO)c1ccc(S(=O)(=O)NCCO)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
CYP2C19 P33261 2/20 0.55
PKM P14618 4/20 0.50
MEP1B Q16820 2/20 0.50
GAA P10253 2/20 0.50
NEK1 Q96PY6 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 1/20 0.43
MMP2 P08253 2/20 0.42
MMP9 P14780 1/20 0.42
NAMPT P43490 1/20 0.42
CYP2D6 P10635 1/20 0.41
POLB P06746 1/20 0.41
IKBKB O14920 1/20 0.40
CHUK O15111 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPK1 P28482 1/20 0.40
GFER P55789 1/20 0.40
ADAMTS4 O75173 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7621847 0.82 ALDH1A1 (0.75) ALDH1A1CYP2C19PKMGAANEK1
SCHEMBL14973311 0.82 TSHR (0.60) ALDH1A1PKMMEP1BNEK1NAMPT
SCHEMBL1018445 0.78 CYP2C19 (0.67) ALDH1A1CYP2C19PKMMEP1BGAA
SCHEMBL1348420 0.78 ALDH1A1 (0.64) ALDH1A1CYP2C19PKMGAAMEN1
SCHEMBL7624023 0.77 ALDH1A1 (0.68) ALDH1A1CYP2C19PKMGAANEK1
SCHEMBL11537516 0.77 CA1 (0.60) ALDH1A1CYP2C19PKMMEP1BGAA
SCHEMBL27418952 0.77 ALDH1A1 (0.58) ALDH1A1CYP2C19PKMMEP1BGAA
SCHEMBL3552882 0.76 SMN1; SMN2 (0.52) ALDH1A1MEP1BGAAMMP2MMP9
SCHEMBL2064330 0.75 CA1 (0.46) ALDH1A1MEP1BPOLBCA12CA1
SCHEMBL13545226 0.74 ALDH1A1 (0.55) ALDH1A1CYP2C19PKMMEP1BGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222667-B1 NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD (CH) 2013-02-20 EP disclosed
CN-101321525-B Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors HOFFMANN LA ROCHE 2013-01-30 CN disclosed
US-8148410-B2 Thiophene derivatives as agonists of S1P1/EDG1 ACTELION PHARMACEUTICALS LTD. (CH) 2012-04-03 US disclosed
US-20100261702-A1 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD. (CH) 2010-10-14 US disclosed
EP-2222667-A2 NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 Actelion Pharmaceuticals Ltd. (CH) 2010-09-01 EP disclosed
EP-1959951-B1 HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-12-23 EP disclosed
WO-2009074950-A2 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD (CH) 2009-06-18 WO disclosed
CN-101321525-A Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors HOFFMANN LA ROCHE (CH) 2008-12-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261702-A1 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 S1PR1, S1PR3, S1PR5 ALDH1A1 1141/4885CYP2C19 3438/4885PKM 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.